Japan, July 14 -- ONCOCEUTICS INC has got intellectual property rights for 'IMIPRIDONE FOR GLIOMA.' Other related details are as follows:
Application Number: JP,2023-118821
Category (FI): A61K31/519,A61P35/00
Stage: PROBLEM TO BE SOLVED: To provide imipridone for glioma.SOLUTION: In particular, imipridone selectively modulates class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and may be used to treat conditions and disorders in need of such modulation, such as cancer. In particular, the cancers relate to the midline structure of the brain, cancers with histone H3 mutations, or both. In addition, methods of identifying whether a subject having these conditions is likely to respond to a treat...